Table 2. Patient and tumour characteristics in the colorectal cancer cohort.
Proficient MMR (n=1,044) | Lynch syndrome (n=27)* | MLH1-hm (n=90) | Double somatic MMR (n=16) | dMMR unexplained (n=5) | |
---|---|---|---|---|---|
Age, median (Q1, Q3) | 71 (61, 78) | 62 (55, 72) | 78 (73, 84) | 69 (57, 79) | 75 (35, 86) |
Gender | |||||
Male | 601 (57.6%) | 22 (81.5%) | 25 (27.8%) | 9 (56.3%) | 2 (40.0%) |
Female | 443 (42.4%) | 5 (18.5%) | 65 (72.2%) | 7 (43.7%) | 3 (60.0%) |
Stage at diagnosis | |||||
I | 193 (18.5%) | 5 (18.5%) | 9 (10.0%) | 1 (6.3%) | 3 (60.0%) |
II | 282 (27.0%) | 16 (59.3%) | 47 (52.2%) | 9 (56.3%) | 2 (40.0%) |
III | 298 (28.5%) | 4 (14.8%) | 24 (26.7%) | 4 (25.0%) | 0 |
IV | 230 (22.0%) | 2 (7.4%) | 6 (6.7%) | 1 (6.3%) | 0 |
Unknown | 41 (3.9%) | 0 | 4 (4.4%) | 1 (6.3%) | 0 |
Location | |||||
Right | 357 (34.7%) | 14 (51.9%) | 76 (86.4%) | 13 (81.3%) | 2 (40.0%) |
Left | 366 (35.5%) | 9 (33.3%) | 8 (9.1%) | 2 (12.5%) | 1 (20.0%) |
Rectum† | 307 (29.8%) | 4 (14.8%) | 4 (4.5%) | 1 (6.2%) | 2 (40.0%) |
Metachronous | 30 (2.9%) | 1 (3.7%) | 6 (6.7%) | 0 | 0 |
Synchronous | 30 (2.9%) | 2 (7.4%) | 4 (4.4%) | 0 | 0 |
dMMR, deficient mismatch repair activity; IHC, immunohistochemistry; MLH1-hm, MLH1 hypermethylation; MMR, mismatch repair; N, number; Q, quartiles.
*Six LS patients with CRC with normal IHC are included here.
†Rectosigmoid location is included with rectum.